Sayantan Raya,
Akhilesh Mishrab,
Tapan Kumar Mandalb,
Biswanath Sac and
Jui Chakraborty*a
aCSIR-Central Glass and Ceramic Research Laboratory, 196, Raja S.C. Mullick Road, Jadavpur, Kolkata-700 032, India. E-mail: jui@cgcri.res.in; Fax: +91-33-24730957; Tel: +91-33-24733476 (3233)
bWest Bengal University of Animal and Fishery Sciences, 37 & 68, Kshudiram Bose Sarani, Belgachia, Kolkata-700037, India
cDepartment of Pharmaceutical Technology, Jadavpur University, Jadavpur, Kolkata-700 032, India
First published on 9th November 2015
The optimization is reported of various process parameters for the development of poly(lactic-co-glycolic acid, PLGA) coating on Mg–Al layered double hydroxide (LDH) nanoparticles intercalated with the anticancer drug methotrexate (MTX). Both double and single emulsion-solvent evaporation techniques were adapted to synthesize the PLGA coated, MTX drug loaded nanoparticles as above, with and without LDH. While keeping some of the process parameters constant, the homogenization speed, concentration of PLGA, LDH-MTX, MTX and surfactants, aqueous and organic phase volume involved in the synthesis of the PLGA-MTX and PLGA-LDH-MTX nanoparticles, were varied and evaluated to obtain the desired particle size range and drug entrapment efficiency for specific use. The optimized and a few selected unoptimized nanoparticles were further assessed for in vitro drug release kinetics and time and dose dependent in vitro cell viability bioassay, in vitro MTX uptake study using human osteosarcoma, MG-63 cell line. The in vivo pharmacokinetic study demonstrated the much higher therapeutic efficacy of the optimized PLGA-LDH-MTX and PLGA-MTX nanoparticles in terms of the enhanced half life of the drug and the slow clearance rate compared to those of the bare MTX drug.
In view of the above, and despite the versatility of MTX as a chemodrug in general and for specific use in osteosarcoma, it is difficult to use it in first-line therapy, either as a single agent or in combination with other anticancer drugs. In this regard, current research worldwide on novel nanoformulations of existing chemodrugs to improve their therapeutic efficacy may overcome the intrinsic problems of the BCS (biopharmaceutics classification system) class IV anticancer drug MTX for this said use. Over the last decade, extensive research has been carried out on carrier mediated drug delivery systems based on the use of liposomes, dendrimers, water soluble polymer and polymer–protein conjugates for some potent chemotherapy agents, e.g., abraxane, doxil etc.19–24 and this research has solved the intrinsic problems, mentioned above, associated with chemodrugs. In addition. these formulations exhibit much higher therapeutic efficacy compared to their bare drug counterparts.
Although drug delivery is a polymer dominated field, the search for an alternative inexpensive and broad spectrum material has undoubtedly arrived at nanophase ceramics which have been used for a long time in biomedical applications.25,26 In the fastest emerging area of drug delivery, their extraordinary characteristics, e.g., size, highly active surfaces, ease of modification, structural advantages, tailor made physical and chemical properties suggest that they can be excellent platforms for drug transportation and controlled release, analogous to their polymeric counterparts.27,28 Pertinent to this area, nanoparticles of layered double hydroxide, a class of anionic clay, have attracted much attention as new age drug delivery vehicles because of their biodegradability, biocompatibility and tailor made anion exchange behavior and non-toxicity.29–32 Broadly, this material is comprised of cationic bilayers and charge balancing anions in the interlayer space, represented by the general formula [M(II)(1−x) M(III)x(OH)2] [An−]x/n·mH2O, where M(II) is a divalent catio and M(III) is a trivalent cation, An− is a gallery anion, x is equal to the ratio M(III)/[M(II) + M(III)], and m is the number of moles of co-intercalated water per formula weight of the compound.33–36 In our earlier work, we reported on the possibility of coating an MTX-loaded LDH (layered double hydroxide) vehicle (LDH-MTX nanohybrid) with an anionic, hydrophobic polymer, PLGA, to improve the overall therapeutic efficacy of MTX while reducing its inherent toxicity, thereby indicating the possibility of its use as a first line chemotherapeutic agent for the treatment of osteosarcoma.37
In continuation of our earlier work, in the present communication we report the optimization of the process parameters for the fabrication of a PLGA [poly(lactic-co-glycolic acid)] coated LDH-MTX (layered double hydroxide-methotrexate) nanohybrid to improve the therapeutic efficacy of the BCS (biopharmaceutics classification system) class IV drug MTX, in terms of improved bioavailability, pharmacokinetic/in vitro release profile, reduced toxicity etc., analogous to the characteristics of first line therapy chemodrugs. To obtain the above, we primarily made an attempt to evaluate the various processing and formulation parameters, e.g., homogenization speed, concentration of PLGA, LDH-MTX, MTX and surfactants, aqueous and organic phase volume etc. that might affect the characteristics of the final dosage form of the optimized PLGA-MTX and PLGA-LDH-MTX nanoformulations. Hence, the whole procedure of optimization helped to validate the preparative conditions of the said dosage form from bench scale to pilot scale, to attain our desired target. The optimized nanoparticles described above were characterized using infrared spectrophotometry, scanning and transmission electron microscopy, dynamic laser scattering and thermal analyses. Drug loading and in vitro release studies were carried out in PBS (phosphate buffered saline) medium at pH 7.4, using high performance liquid chromatography (HPLC). The time and dose dependent cell viability assay of the optimized PLGA coated MTX and LDH-MTX using the human osteosarcoma cell line (MG-63) exhibited a higher efficacy compared to that obtained with the pure MTX drug, (active pharmaceutical ingredient, API) for time periods of 48, 72 and 96 h, while the pharmacokinetic (healthy) study carried out using the New Zealand White rabbit model revealed an enhanced elimination half life (t1/2) of the drug, with a much slower clearance rate and a longer retention time for the optimized formulation, compared to its bare MTX counterpart.
Scheme 2 Optimized technique for the synthesis of PLGA-LDH-MTX nanoparticles by a W1/O/W2 double emulsion-solvent evaporation method. |
Scheme 3 Development of PLGA-MTX nanoparticle by an O/W single emulsification-solvent evaporation method. |
The resulting sample was collected by centrifugation at 8519g for 10 min and was washed several times with decarbonated water to remove the residual non-ionic surfactant, PVA. Finally, the particles were resuspended in a cryoprotectant (1% w/v mannitol solution) and freeze dried at-82 °C at a vacuum pressure of 20 Pa. Each sample was prepared in triplicate to check the reproducibility of the process.44,45
The methods described above were optimized, with regard to all the synthesis and processing parameters.
All of the experiments were carried out in triplicate and the errors were expressed as SD.
All of these experiments were repeated at least three times to check the reproducibility of the results. Fourier-transform infrared spectra (FTIR) were recorded (Perkin-Elmer Frontier™ IR/FIR, Waltham, USA) using KBr (Sigma Aldrich, >99% pure) pellets (sample: KBr 1:100 by weight) at 400–4000 cm−1 with an average of 50 scans to improve the signal to noise ratio. The physical compatibility of MTX drug entrapped in the sample PLGA-LDH-MTX and PLGA-MTX was determined by differential scanning calorimetry (STA 449 F3 Jupiter®, NETZSCH, Germany). In this, ∼5 mg of MTX, LDH, LDH-MTX, PLGA, PLGA-LDH-MTX, PLGA-MTX, physical mixture of MTX and PLGA, and (MTX:LDH in 1:1 ratio by weight) as placebo nanoparticles were sealed in standard aluminum pans with lids and were heated from ambient to 500 °C (@ 5 °C min−1) in a nitrogen atmosphere. Particle size, morphology and crystallographic analyses of PLGA-MTX and PLGA-LDH-MTX nanoparticles were studied using transmission electron microscopy, TEM (FEI Tecnai F30 G2 S-Twin, The Netherlands) at 300 kV. The grid for the TEM study was prepared by dropping a microdroplet of a suspension of LDH powder in isopropyl alcohol on to a 400 mesh carbon-coated copper grid and drying the excess solvent naturally. Microanalyses of the samples (elemental composition) were performed using energy dispersive spectroscopy (EDS) with a low system background (<1% spurious peaks), high P/B ratio (Fiori number > 4000) with an Si–Li detector attached to the TEM equipment.
Fig. 1 Effect of homogenization speed on (A) particle size (mean diameter) and (B) percentage of drug entrapment efficiency of PLGA-MTX and PLGA-LDH-MTX nanoparticles. |
Drug entrapment efficiency of both the nanoparticles, increased with an increase in the polymer concentration up to a certain limit, in the organic phase (Fig. 2, panel B). An increase in the amount of polymer increases the viscosity of the organic phase which in turn hinders drug diffusion from the organic phase to the aqueous phase.59,60 In the case of the PLGA coated MTX nanoparticles, it might be possible that the increase in the polymer concentration increased the diameter of the nanoparticles, and thereby increased the diffusion pathway of the drug into the aqueous phase, reducing the drug loss through diffusion and increasing the drug content.61,62 In the case of PLGA coated LDH-MTX, it was observed that there was an initial increase of entrapment efficiency followed by a marked decrease, on account of the substantial variation in particle size as demonstrated above (Fig. 2, panel A). In addition to this, considering the thermodynamic stability of the system, marked by balancing a number of molecular interactive forces at the interface of the hydrophilic LDH core intercalated with the hydrophobic MTX, encapsulated altogether in the hydrophobic PLGA shell is achieved until a limit concentration, beyond which, the physical phenomenon of polymer chain loosening starts, indicating a possibility of drug loss and thereby reduction of the entrapment efficiency as shown in Fig. 2, panel B. See Table S1† in ESI for detail information about the related parameters.
Fig. 2 Effect of polymer (PLGA) concentration on the (A) particle size and (B) percentage of drug entrapment efficiency of PLGA-MTX and PLGA-LDH-MTX nanoparticles. |
Fig. 3 Effect of surfactant concentration (Span 80) on (a) particle size and (b) percentage of drug entrapment efficiency of PLGA-LDH-MTX nanoparticles. |
Fig. 4 Effect of the surfactant concentration (PVA, Tween 80) on (A) particle size distribution. (B) Percentage of drug entrapment efficiency. |
With regard to drug entrapment efficiency, in the case of PLGA-MTX, (Fig. 4, panel B) an optimum concentration of PVA tends to reduce the particle size as above and is thereby associated with the larger surface area of the nanoparticles which enhances the possibility of the drug molecules being attached to the nanoparticle surfaces, leading to a higher drug entrapment efficiency.65 In contrast, for PLGA-LDH-MTX, (Fig. 4, panel B) an enhanced concentration of Tween 80 in the external aqueous phase helps to reduce the entrapment efficiency of the nanoparticles on account of the hydrophilic LDH core of the PLGA coated surface active particles which aids the slow diffusion of MTX into the external aqueous phase, leading to a linear pattern of decrease in entrapment efficiency.66 See Table S2† in ESI for detail information about the related parameters.
Fig. 5 Effect of volume of organic and aqueous phase on (A and C) percentage of drug entrapment efficiency and (B and D) particle size of PLGA-MTX and PLGA-LDH-MTX nanoparticles. |
Fig. 5, panel C shows that as the aqueous phase volume increased entrapment efficiency also increased for both of the nanoparticles PLGA-MTX and PLGA coated LDH-MTX produced by homogenization.59,68 It is clearly observed that increasing the aqueous volume results in an increase of drug entrapment efficiency; this could be due to less aggregation of the particles in a larger volume.69 This condition aids in faster solidification of the polymer present in the organic phase, across the phase boundary, leading to an increased particle size and thereby, higher drug entrapment efficiency.
With regard to the mean diameter, Fig. 5, panel D shows an increasing trend of the same for PLGA-LDH-MTX and PLGA-MTX both, with increasing external aqueous phase volume. A probable explanation is that with increasing the external volume, the shear forces to break the emulsion droplets become smaller yielding larger emulsified droplets which in turn results in larger PLGA nanoparticles.59,60,69
Fig. 6, panel B shows that an increase in loading of the drug increases the mean diameter of the nanoparticles along with their polydispersity index. It can be explained that the greater amount of drug results in a highly concentrated dispersed phase, making the mutual dispersion of the organic and the aqueous phases difficult, thereby forming larger particles.59,72,73
Fig. 6 Effect of drug concentration in organic/aqueous phase on (A) percentage entrapment efficiency and (B) particle size of PLGA-MTX and PLGA-LDH-MTX nanoparticles. |
After optimization of all the process parameters, the optimized PLGA-MTX nanoparticles were evaluated for the determination of the residual surfactant, PVA used in the single-emulsion solvent evaporation method. A fraction of the partially hydrolyzed (87–90%) PVA used as the surfactant to stabilize the emulsion forms a strong network on the PLGA surface using its hydrophobic vinyl acetate copolymer part as an anchor at the oil–water interface, for binding to the PLGA surface as above, and this could not be removed.74 This part was estimated to be 20 μg g−1 of the optimized formulation of PLGA-MTX nanoparticles, following the method as demonstrated in the experimental section.
The experimental yield of the optimized batch of PLGA-MTX was 66.9% and ∼71.43% for PLGA-LDH-MTX (Table 3). See eqn (S4) and (S5) in ESI.†
The powder X-ray diffraction (XRD) patterns of PLGA polymer, pristine-LDH, LDH-MTX and the optimized batches of the PLGA-LDH-MTX and PLGA-MTX nanoparticles are shown in Fig. 7. The pattern is characteristic of the hydrotalcite-like phase comprising hexagonal lattice with rhombohedral space group.38,40 The d spacing corresponding to the (003) plane of pristine LDH at 8.25 Å (Fig. 7(d)) shifted considerably on intercalation of the MTX drug to 21.35 Å (Fig. 7(b) and c), this is marked approximately by a pair of arrows in LDH-MTX and PLGA-LDH-MTX, confirming the encapsulation of LDH-MTX as prepared within the PLGA coating. Considering the thickness of the Brucite layers to be 4.8 Å, the gallery height of the LDH-MTX nanohybrid material is found to be (21.35–4.8) Å = 16.55 Å (Scheme 1, X′ Å). The longitudinal molecular length of MTX is 21.2 Å; hence, the drug molecule is tilted at an angular configuration of 51.5° within the layered framework of the Brucite and is held in place by a charge based interaction between the anionic counterpart of the MTX drug and the cationic Brucite layers.38,39 The pristine LDHs exhibited a series of well developed (0 0 l) reflections (Fig. 7(d), JCPDS file no. 350964), which were also clearly seen with both the PLGA coated and the uncoated LDH-MTX (Fig. 7(b and c)). Almost similar PXRD patterns could be obtained in the cases LDH-MTX and its PLGA coated counterpart (Fig. 7(b and c)), except for the hump like peak at around 20° of the diffraction angle, marked by arrow (Fig. 7(c)), due to the presence of PLGA polymer (Fig. 7(a)).75 The high intensity peaks at 2θ = 13.5, 14.3, 19.4, 27.8 and 30° in Fig. 7(f) confirm the crystalline nature of the pure drug, MTX76,77 whereas, in Fig. 7(e), the presence of a small hump corresponding to the PLGA78 matrix is supported in turn by the above peaks of both low and medium intensities of MTX drug, for the PLGA-MTX structure, suggesting molecular dispersion of the MTX drug in the PLGA polymer matrix.
Fig. 7 Powder X-ray diffraction patterns of (a) PLGA (b) LDH–MTX (c) PLGA-LDH-MTX (d) LDH (e) PLGA-MTX (f) MTX. |
Fig. 8 exhibits the major vibration bands corresponding to the compositions as mentioned. Fig. 8(b) shows vibration bands of PLGA, due to stretching of alkyl group (2850–3000 cm−1), carbonyl CO stretching (1700–1800 cm−1), C–O stretching (1050–1250 cm−1) due to the presence of an ester group and –OH stretching (3200–3500 cm−1).79,80 The broad hump at 3435 cm−1 in Fig. 8(g) is due to the stretching vibration of both structural hydroxyl and interlayer water molecules of the Brucite layers of pristine LDH.37–39,41 The bands of medium intensity in the lower frequency range from 433 to 689 cm−1, were due to M–O vibration and M–OH bending of the Brucite-like layers, while the presence of a band of high intensity at 1387 cm−1 signifies the presence of NO3− anions in the interlayer space of pristine LDH (arrow marked). Interestingly, the intensity of this band was reduced considerably in LDH-MTX (Fig. 8(c)), shown by an arrow, suggesting intercalation of the drug molecule leading to partial removal of the NO3− anion.37,38,41 This is in corroboration with the presence of symmetric and asymmetric stretching vibration of the carboxylate group of MTX at 1370 and 1545 cm−1 respectively, due to –COO (νCOO−), and at 1409 and 1620 cm−1 due to CC stretching of MTX,40,81,82 confirming MTX intercalation in LDH-MTX, as above. Other vibration bands of low and medium intensity are in line with our previous works. The vibration band of medium intensity at 1774 cm−1 is attributed to CO stretching of the PLGA (Fig. 8(d)) hydrocarbon chain, remains almost unaltered in PLGA coated MTX/LDH-MTX nanoparticle, confirming no chemical interaction or bond formation between the PLGA coating and the encapsulated LDH-MTX/MTX (Fig. 8(d and e)), marked by a dotted rectangle. In addition to this, the vibration bands of low intensities corresponding to CC stretching of MTX at around 1620 cm−1 is a good proof of the successful entrapment of MTX, both in PLGA-MTX and PLGA-LDH-MTX nanoparticles (Fig. 8(d and e)). No significant peak corresponding to the presence of PVA (Fig. 8(a)) adsorbed on the PLGA-MTX nanoparticles could be marked in the characteristic pattern of PLGA-MTX (Fig. 8(d)).37 This could be attributed to the negligible amount of the residual PVA present in the optimized formulation of PLGA-MTX nanoparticles. Fig. 8(f) exhibits the major peaks of MTX at 3413 (–NH stretch), 1654 cm−1 (–COOH), 1639 cm−1 (–CONH), 805 cm−1 (aromatic stretch out-of-plane bend), confirming the purity of the drug.82
The optimized nanoparticles were evaluated for particle size and zeta potential and the results are shown in Table 1.The size distribution is depicted in Fig. 9. It is evident that with an increase in the polymer concentration in MTX/LDH-MTX coating, the corresponding particle size was found to increase up to a certain concentration of polymer with an increase in the polydispersity index (PDI). Finally, in the optimized batch, comprising 2:1 (w/w) PLGA:MTX/PLGA:LDH-MTX ratio, the particle size was found to be 120–180 nm for PLGA-MTX and 180–250 nm for PLGA-LDH-MTX (Fig. 9(b and c)) with PDI of 0.163 and 0.217, respectively. The zeta potential values for optimized batches of PLGA-MTX and PLGA-LDH-MTX were found to be in the range of −38.34 and −33.62 mV respectively, indicating the excellent stability of the nanoparticles in aqueous suspensions.37,41 The negative zeta potential values are due to the presence of an end terminal carboxylic acid group in PLGA and a carbonyl group in the PLGA block.83 The advantage of this negatively charged particle size over a positively charged one, is less induction of inflammation and lower induction of T-cell proliferation and cytokines production and secretion compared to the cationic nanoparticle, which results in less damage to the erythrocyte membrane.84,85 The size distribution pattern of the particles plays an important role in determining the drug release behavior, their feasibility for intravenous administration as well as their fate in vivo. Due to smaller size of the particles (<200 nm), they tend to accumulate in the tumor sites because of the facilitated extravasations, which can prevent spleen filtering.86,87 Further a lower PDI indicates enhanced homogeneity of the nanosuspension which was observed with both the PLGA-MTX and PLGA-LDH-MTX systems described above.37
Formulation | Drug:polymer ratio (w/w) | Particle size (nm) | Zeta potential | % yield | % DEE |
---|---|---|---|---|---|
PLGA-MTX | 1:2 | 165 ± 1.37 | −38.34 | 66.9 ± 0.34 | 35.20 ± 4.62 |
PLGA-LDH-MTX | 1:2 | 205 ± 2.79 | −33.62 | 71.43 ± 2.84 | 65.12 ± 3.26 |
Fig. 9 Particle size distribution (intensity) of (a) PLGA (b) PLGA-MTX (c) PLGA-LDH-MTX of the optimized batch of nanoparticles. |
The FESEM images presented in Fig. 10 depict the wide variation in the size and shape of the particles formed under different process parameters, e.g., homogenization speed, stabilizer concentration etc. Without the LDH nanoparticles, the optimized batch of PLGA coated MTX system exhibits a globular morphology with the formation of clusters of particles of a wide variety of sizes, e.g., 250 nm to 1.5 μm, as shown in Fig. 10(a). The single emulsion technique used for the preparation of PLGA-MTX, involves the use of a low concentration (0.25% w/v) of the water soluble emulsifier, PVA, and does not reduce the interfacial tension between the lipophilic and hydrophilic phases of the microemulsion,88 leading to aggregation and cluster formation of the resulting nanoparticles. A four-fold increase in the PVA concentration leads to better dispersion of the particles, as shown in Fig. 10(b), whereas, with an eight-fold increase as detailed above, an almost uniform particle distribution of PLGA-MTX is observed, without much aggregation, Fig. 10(c). However, the presence of the polar hydrogen bond in the aqueous dispersion phase of the emulsion leads to flocculation of the particles to some extent, as is evident from Fig. 10(c).
In the case of PLGA-LDH-MTX, Fig. 10(d) reveals many aggregated particles, on account of the low concentration (0.15%, w/v) of the hydrophilic emulsifier, Tween 80 (HLB value: 15) in the aqueous phase of the secondary emulsion. An increase in the concentration to an extent of more than ten times that of the optimized batch, Fig. 10(e) exhibits the presence of aggregation free, discrete and monodispersed PLGA-LDH-MTX particles in the external aqueous phase. Interestingly, on dispersion of the internal/dispersed phase (W1/O) in the continuous medium (W2), the entropy of the system is enhanced by quite a few times. This is taken care of by the substituted side chain of Tween 80, by entrapping the particles leading to dispersion of the particles without any aggregation having the minimum surface area, leading to almost round shaped morphology, in the size range 180–250 nm, coated with PLGA. This corresponds to the optimized batch of the synthesis, w.r.t to all the experimental parameters, as abovementioned, that matches with our observation with regard to particle size analysis using DLS (Fig. 9). Fig. 10(f) confirms the presence of LDH-MTX nanocrystals within the PLGA encapsulated structure, exhibited by the edge of a regular plate like shape, as show by the arrow mark.37
Fig. 11(a) shows the encapsulation of MTX in PLGA polymer of the optimized batch. In the presence of PVA as the non-ionic emulsion stabilizer/emulsifier, the hydroxyl groups, –OH, can be specifically adsorbed on the emulsion droplet, thus resulting in the formation of a charge, which paves the way for the formation of an electrical double layer, thereby leading to mutual repulsion between the emulsified particles. However, in the aqueous external phase, the hydrogen bonded network plays a role in flocculating the emulsified PLGA-MTX particles to obtain clusters as shown in Fig. 11(a). The SAD pattern of the particles, shows diffuse rings, characteristic of the presence of the amorphous PLGA polymer (Fig. 11(b)). In another image, a magnified view exhibits a discrete particle having perfectly spherical morphology, with a smooth surface, comprising the drug within the polymer encapsulation (marked by an arrow) as is evident from Fig. 11(c).
In the case of the LDH-MTX counterpart, Fig. 11(d) exhibits the optimized batch of the nanoparticles precipitated by the double emulsion solvent evaporation method as detailed above. An optimum concentration of the non-ionic surfactant, Tween 80 (PEG-20 sorbitan monoleate), with high HLB value (15), facilitates agglomeration free dispersion of the oil based dispersed phase, after solvent evaporation, leading to encapsulation of the LDH-MTX nanoparticles in the PLGA coating. Fig. 11(e) exhibits the SAD pattern of the PLGA-LDH-MTX nanoparticles, showing a pair of (00l) reflections characteristic of the LDH-MTX structure, corroborating our findings of the XRD analysis, shown in Fig. 7(b).40 A discrete PLGA-LDH-MTX particle shown in Fig. 11(f) exhibits the planar structure of the LDH-MTX nanohybrid embedded in the polymer matrix (marked by an arrow). See Fig. S2† for EDX data of PLGA-LDH-MTX.
The DSC thermogram of MTX in Fig. 12(a) shows a broad endothermic melting peak at around 240 °C,89 but in the case of LDH-MTX nanoparticles, the drug melting peak was shifted to a lower temperature of 228 °C, on account of the melting of the crystalline drug and the formation of dispersion at the molecular level within the ceramic matrix, confirming entrapment of the drug in the LDH interlayer space. In the case of PLGA, an endothermic peak at ∼54 °C corresponds to its glass transition temperature in the range of 40–60 °C.73 A second hump for PLGA at around 290 °C is due to the evaporation of the monomer D,L-lactide.42,90,91 In the case of the physical mixture of PLGA and MTX (1:1 ratio) a small endothermic hump was observed at 250 °C corresponding to the melting endotherm of the pure drug. In the case of the optimized PLGA-MTX and PLGA-LDH-MTX nanoparticles (Fig. 12, panels e and f), the absence of the melting peak of MTX confirms that drug crystals completely dissolve inside the polymeric matrix or ceramic–polymeric conjugate matrix during the scanning of temperatures up to the melting value or because the drug remained dispersed at the molecular level inside the nanoparticles.
Fig. 12 DSC of (a) MTX (b) LDH-MTX (c) PLGA (d) PLGA-MTX physical mixture (e) PLGA-MTX and (f) PLGA-LDH-MTX nanoparticles. |
The drug release from a nanoparticulate matrix system, in which the drug is uniformly embedded, generally occurs by diffusion or erosion of the matrix. Several parameters can affect the drug release rate from matrix systems, in addition to the particle size, molecular weight and ratio of the constituent monomers, e.g., lactide to glycolide ratio of the polymer used as matrix also, influences the drug release kinetics to a large extent.92,93 In the present study, the in vitro drug release study was carried out in PBS of pH 7.4 for some of the selected unoptimized PLGA-LDH-MTX and PLGA-MTX formulations, compared to the corresponding optimized ones, to understand and compare the possible differences in the in vitro drug release profile. Herewith, PLGA-MTX (L) (Fig. 13), panel A, subpanel (a) corresponds to a lower particle mean diameter (<120 nm) with a low drug entrapment efficiency, exhibiting a faster release of the drug from the matrix system within a 12 h period due to a higher surface area (on account of the lower particle diameter) and a low entrapment efficiency.57 On the other hand, PLGA-MTX (H) (Fig. 13, panel A, subpanel c) corresponds to a high entrapment efficiency with a higher particle size (∼2 μm) (Table 3), leading to the slower release of the drug for a much longer period of 144 h, which is much higher than our desired value (120–180 nm as above). In the case of PLGA-LDH-MTX unoptimized formulations [PLGA-LDH-MTX (L) and PLGA-LDH-MTX (H) ] exhibited at subpanels (d) and (f) of Fig. 13(A), almost similar patterns are observed. All the relevant physicochemical properties of the unoptimized PLGA-MTX (L&H) and PLGA-LDH-MTX (L&H) are listed in Table 3.
The cumulative release profile of the optimized PLGA-MTX nanoparticles exhibited in Fig. 13, panel A, subpanel b, shows an initial burst release pattern. In the case of PLGA-MTX, 90.67% of the encapsulated MTX was released during the first two days, followed by a slower release rate (10%) up to a period of 5 days, exhibiting a biphasic release pattern. In the first phase, the low molecular weight PLGA polymer used in the present case undergoes fast hydrolysis in the release medium, leading to loosening of the polymer chains and thereby fast diffusion of the entrapped MTX drug through the empty pores formed, within a short period of time. For the low molecular weight polymer, the lower chain length of PLGA lowers its lipophilicity, resulting in lower solubility of the MTX drug in the polymer, initiating the burst release of a substantial amount of drug (90.67%) during the first two days only. In phase 2, the rate of diffusion becomes much slower being close to equilibrium conditions.94
In the case of optimized PLGA-LDH-MTX, a similar biphasic release pattern was observed, as shown in Fig. 13, panel A, subpanel e. During the first 5 days, 81.50% of MTX was released at a constant and fast rate. Following this, a slower release rate was observed and nearly 18.50% of the drug was released over the next 7 days. In phase 1, the surface adsorbed drug was released rapidly into the aqueous phase, contributing to the burst release, although it was slower compared to PLGA-MTX on account of the loosening of the PLGA chain followed by slow diffusion of the MTX drug, intercalated within the interlayer space of the LDH matrix by an anion exchange process only. In phase 2, complete rupture of the PLGA chain takes place, leading to exposure of the remaining LDH-MTX in the structure, in contact with the release medium, followed by diffusion of the drug slowly into the medium by an anion exchange process.37 Hence, as is clearly evident, the drug release in the case of PLGA-LDH-MTX is extended for a longer period of time compared to PLGA-MTX, on account of the presence of the entrapped LDH-MTX nanohybrid, which facilitates release of the MTX drug from its interlayer space only by an anion exchange mechanism, in both the phases of release.37
To study the exact release mechanism, data obtained from the in vitro release studies were fitted into various kinetic equations95–97 (Table 2) to find out the mechanism of methotrexate release from both PLGA-LDH-MTX and PLGA-MTX. On fitting all the four kinetic models in the release kinetic data of MTX, it was found that the Higuchi model is the most satisfactory for describing the mechanism of the release of MTX from the PLGA-LDH-MTX at pH 7.4, with correlation coefficient values 0.9944 (Fig. 13 panel C). This indicated that the release of MTX from PLGA-LDH-MTX followed diffusion controlled release.97 Further, the drug release data was fitted to the Korsmeyer–Peppas (K–P) model to determine the value of the diffusion exponent (n). The value of n for a spherical system, <0.43 indicates Fickian release, 0.43 < n < 0.85 indicates non-Fickian release; n > 0.85 indicates case II release.96 The n-value obtained for PLGA-LDH-MTX after the K–P plot was in the range of 0.43–0.85 indicating that release followed anomalous non-Fickian transport, it could be suggested that the release is related to a combination of both diffusion and dissolution processes.96,98 For PLGA-MTX, the correlation coefficient of 0.9977 (Fig. 13 panel B) indicates a first order model of release kinetics of MTX, i.e., the cumulative release of the drug is directly proportional to the concentration of the drug in the PLGA polymer matrix.95 From the K–P model, it was found that the PLGA-MTX formulation (n = 0.504) showed anomalous transport kinetics i.e., a combined mechanism of pure diffusion and dissolution. The calibration curve of MTX in PBS and some other fitting plots of MTX release from the optimized batches of PLGA-MTX and PLGA-LDH-MTX nanoparticles are shown in Fig S3 and S4 of ESI.†
Optimized nanoparticles | Zero order | First order | Higuchi | Korsmeyer Peppas | n values |
---|---|---|---|---|---|
PLGA-MTX | 0.9968 | 0.9977 | 0.9950 | 0.9907 | 0.504 |
PLGA-LDH-MTX | 0.9629 | 0.9897 | 0.9944 | 0.9914 | 0.74 |
The in vitro cell viability assays are carefully considered before a new formulation can be tried in animal or human subjects. Such methods are primarily employed to identify potentially hazardous chemical substances and to confirm the lack of toxicity at the early stages of development of potentially useful new therapeutic.37,99 Based on this concept, in the present study, we have measured how effective the PLGA encapsulated systems, PLGA-MTX and PLGA-LDH-MTX nanoparticles are to inhibit the growth of the bone cancer cells, in a time and dose dependent manner. Hence, four different trial concentrations of the drug MTX, PLGA, LDH, PLGA-MTX, PLGA-LDH-MTX were studied in multiples of 25, e.g., 25, 50, 75 and 100 μg ml−1, at four different time points of 24, 48, 72 and 96 h on the human osteosarcoma cell line, MG-63 (Fig. 14). The concentrations mentioned herewith were chosen randomly to undertake the trial experiment as above for estimation of efficacy of the newly developed nanoparticles, PLGA-MTX and PLGA-LDH-MTX. Interestingly, the results revealed more than 97% cell viability for the cases using PLGA and LDH, confirming their non-toxicity100,101 for the encapsulation of MTX or LDH-MTX, irrespective of time and dose. However, the optimized nanoparticles, PLGA-MTX and PLGA-LDH-MTX exhibited cytotoxicity in a time and dose dependent manner, along with MTX. At 24 h, almost no effect of the same could be observed on the human osteosarcoma cells, whereas, on completion of two days (48 h), a marked reduction on cell viability (≈50%) was observed when MG-63 cells were incubated with 100 μg ml−1 of pure MTX at 37 °C, whereas for PLGA-MTX it showed ≈50% cell inhibition at half the concentration as above (50 μg ml−1) and around 60% cell inhibition at 75 μg ml−1, around 70% inhibition at 100 μg ml−1 respectively (Fig. 14, panel B). On the contrary, at the same time period (48 h), PLGA-LDH-MTX nanoparticles exhibit 50% cell inhibition only at the higher concentration range of 75 and 100 μg ml−1. As evident, better results were obtained for PLGA-MTX nanoparticles compared with those obtained for bare MTX and PLGA-LDH-MTX at 50, 75 and 100 μg ml−1 concentrations on account of their smaller particle size (120–180 nm) which leads to easy cellular uptake through the anionic cell membrane, by an endocytosis mechanism. This corroborates with our observation at 72 h (Fig. 14, panel C). The longest incubation time of 96 h was also considered in our work, based on the slow and controlled release of MTX from the polymer coated PLGA-LDH-MTX system which indicated the possibility of better efficacy of this system over an extended time period (Fig. 14, panel D). It was clearly observed that both the polymer coated formulations, PLGA-MTX and PLGA-LDH-MTX inhibit the cancer cell growth at a much higher scale compared to bare MTX, at concentrations of 50, 75 and 100 μg ml−1. Interestingly, incubation time is a critical factor here: at 24 h, no significant effect could be noticed for the above polymer coated optimized formulations at a concentration range of 50, 75 and 100 μg ml−1, while, after a period of 96 h incubation, a marked reduction in cell viability could be achieved, up to the extent of 90–95%. Hence, the present study not only shows the time dependent efficacy of the optimized polymer coated nanoparticles compared to bare MTX drug on MG-63 cells, but also indicates that the lower doses (e.g., 75 μg ml−1) of the optimized batches of PLGA-MTX and PLGA-LDH-MTX nanoparticles are better than the higher dosage (e.g., 100 μg ml−1) of pure MTX in a time period of 96 h.102
For unoptimized formulations corresponding to the optimized PLGA-MTX and PLGA-LDH-MTX, in the present case, we have considered PLGA-MTX (L) and (H) as well as PLGA-LDH-MTX (L) and (H) respectively, for the in vitro cell viability study using the human osteosarcoma (MG-63) cell line. Herewith, we have taken into account a fixed concentration of MTX drug at 75 μg ml−1, at four different time points of 24, 48, 72 and 96 h. The concentration of the drug as above was fixed based on our earlier data as exhibited in panel A to D of Fig. 14, which confirms the highest efficacy of both the optimized formulations of PLGA-MTX and PLGA-LDH-MTX nanoparticles in a period of 96 h. In the case of PLGA-MTX (L) and PLGA-LDH-MTX (L), the smaller particle mean diameter (<120 nm) aids in faster endocytosis of the nanoparticles along with faster release of the drug within the cancer cell, leading to a consolidated effect (cancer cell growth inhibition of around 50–55%) of the same during the time period of 24 to 96 h. For PLGA-MTX (H) and PLGA-LDH-MTX (H), a higher particle mean diameter (size range: 800 nm to 2 μm) hinders the endocytosis mechanism and at the same time, slow release of the drug, outside the cell, in the DMEM medium leads to slow diffusion of the drug into the cell and hence the delay in the growth inhibition process (20–30% in a period of 24 to 96 h).
For the concentrations 25 and 50 μg ml−1 in the lower range and 100 μg ml−1 in the higher range, the in vitro cell viability assay was carried out using the unoptimised set of formulations [PLGA-MTX (L) and (H) and PLGA-LDH-MTX (L) and (H)] and we obtained statistically insignificant results which could not be presented here.
The cellular uptake of MTX drug from the optimized PLGA-MTX and PLGA-LDH-MTX nanoparticles in the MG-63 cell line at three different time points of 6, 15 and 24 h respectively is shown in Fig. 15, panel A. The study shows that the drug uptake was significantly increased with respect to time in both the above cases. However, in the case of PLGA-MTX, on account of its smaller particle size (120–180 nm), faster insertion in the cell takes place by an endocytosis mechanism compared to PLGA-LDH-MTX. This leads to higher cellular uptake in terms of quantity of MTX (3.34 μg ml−1 at 6 h, 7.91 μg ml−1 at 15 h and 14.15 μg ml−1 at 24 h) in the former case, whereas in the later case, not only the larger particle size (180–250 nm) hinders the insertion of the drug in the cell by endocytosis mechanism, but, at the same time, slower release of the encapsulated drug within the cell takes place on account of the presence of a nanoceramic matrix that in turn is coated with PLGA polymer (2.43 μg ml−1 at 6 h, 4.13 μg ml−1 at 15 h and 11.24 μg ml−1 at 24 h).
In the case of the unoptimized set of formulations [PLGA-MTX (L) and (H) and PLGA-LDH-MTX (L) and (H)] (Fig. 15, panel B), we compared PLGA-MTX (L) with PLGA-LDH-MTX (L) and determined that the MTX uptake in the cell from the above nanoparticles follows a slightly increasing trend at the initial time points of 6 and 15 h, on account of endocytosis and hence MTX is released from a large number of nanoparticles (due to small size, <120 nm) (Table 3) whereas, not much distinct differences could be observed at 24 h, on account of the low entrapment efficiency (Table 3) of the nanoparticles. In the case of the unoptimized PLGA-MTX (H) and PLGA-LDH-MTX (H) nanoparticles, the MTX uptake in the cell was almost below the detection level on account of the large particle size (800 nm to 2 μm) (Table 3), as above leading to minimum/almost no insertion of the nanoparticles within the cell.
Formulation | Drug: polymer ratio (w/w) | Homogenization speed (rpm) | Particle size (nm) | Zeta potential | % yield | % EE |
---|---|---|---|---|---|---|
PLGA-MTX- L | 1:2 | 15000 | 112 ± 1.79 | −32.04 | 45.40 ± 1.74 | 15.84 ± 2.16 |
PLGA-MTX-H | 1:2 | 5000 | 1865 ± 1.90 | −34.14 | 59.33 ± 3.39 | 62.28 ± 1.33 |
PLGA-LDH-MTX-L | 1:2 | 15000 | 110 ± 2.22 | −33.76 | 51.33 ± 6.14 | 4.39 ± 4.36 |
PLGA-LDH-MTX-H | 1:2 | 5000 | 1980 ± 3.43 | −34.33 | 63.88 ± 1.09 | 89.96 ± 4.36 |
The pharmacokinetic parameters of the optimized batches of PLGA-MTX and PLGA-LDH-MTX were compared with those for the pure MTX drug (API), after intravenous administration. The plasma drug concentration profile and the corresponding pharmacokinetic parameters are summarized in Fig. 16, panel A, B and C and in Table 4. The values for the area under the curve-versus-time curve (AUC0−∞, 1.304 mg h−1 ml−1), and t1/2 (4.68 h) of PLGA-MTX nanoparticles were found to be much higher (6 times for AUC and 20 times for t1/2) than the pure drug MTX (AUC0−∞, 0.266 mg h−1 ml−1, t1/2 0.24 h), after being encapsulated in PLGA. In the case of PLGA-LDH-MTX nanoparticles, AUC0−∞ was found to be 2.155 mg h−1 ml−1 and t1/2 was 15.4 h which is almost 10-fold higher than the corresponding parameter for the pure drug and almost 75-fold higher than the t1/2 for the pure drug. It is clearly observed that the PLGA-LDH-MTX nanoparticles exhibited a longer retention time. The plasma drug concentration for PLGA-MTX nanoparticles was detectable up to 72 h (Fig. 16, panel B) whereas for PLGA-LDH-MTX it was detectable up to 200 h (Fig. 15, panel C) which may be due to the slow clearance rate leading to enhancement in elimination half life and correlates well with in vitro release data.103 The results showed that the nanoparticles had significantly improved the exposure, reduced the clearance, and slightly raised the volume of distribution compared to the pure MTX drug.104 This may be attributed to the sustained release of MTX from PLGA-MTX and PLGA-LDH-MTX nanoparticles respectively. In the case of the PLGA-MTX, such release is diffusion controlled, leading to retention of the drug (marked by an arrow, Fig. 16, panel B) in the elimination phase, for PLGA-LDH-MTX, release of the drug via an anion exchange mechanism leads to a longer retention of the drug, compared to PLGA-MTX and MTX (marked by arrows, Fig. 16, panel C). The in vitro release profile correlated well with the release results of the in vivo plasma drug concentration profile measured during the pharmacokinetics experiment, using intravenous injection. The reason for the sustained release was considered to be due to the relatively long circulation of the nanoparticles and the low clearance rate when compared to the pure drug. Nanoparticles showed significant changes in pharmacokinetic profile compared to the pure drug. It can be observed that there was a statistically significant difference (p < 0.05) in the pharmacokinetic parameters when MTX was formulated in the form of nanoparticles at a 95% confidence interval (CI).
Fig. 16 Pharmacokinetic release profile of (A) MTX (B) optimized PLGA-MTX nanoparticles and (C) optimized PLGA-LDH-MTX nanoparticles. |
PK parameters | Units | (MTX) | PLGA-MTX | PLGA-LDH-MTX |
---|---|---|---|---|
AUC0−∞ | μg h ml−1 | 266.09 | 1304 | 2155.5 |
Elimination half life (t1/2) | h | 0.24 | 4.68 | 15.4 |
Elimination rate (Kel) | l h−1 | 2.88 | 0.148 | 0.045 |
Volume of distribution (Vd) | L kg−1 | 0.406 | 0.60 | 0.8 |
Clearance (Cl) | mL h−1 kg−1 | 0.731 | 0.0555 | 0.0225 |
Footnote |
† Electronic supplementary information (ESI) available. See DOI: 10.1039/c5ra15859a |
This journal is © The Royal Society of Chemistry 2015 |